Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on March 31, 2026. The filing serves to announce the results of operations for the fiscal year ended December 31, 2025, which were originally detailed in a press release issued on November 14, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) but are not explicitly stated in the body of this Form 8-K.
Material Changes
The filing references business updates and fiscal year results but does not detail specific material changes versus prior periods within the text of the report itself.
Guidance, Outlook, and Risks
The report includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2026) for specific financial figures regarding the fiscal year ended December 31, 2025.
- Verify the discrepancy between the press release date (November 14, 2025) and the 8-K filing date (March 31, 2026) to understand the context of the delayed filing.
- Confirm the status of the company's cash position and burn rate, as these are not listed in the summary text.
- Check for any subsequent filings that may incorporate the press release by reference.